TLR9 and head and neck squamous cell carcinoma: Similarly, TLR9 agonist SD-101, which is given as an intratumoral injection, has been evaluated in a phase I/II trial in combination with pembrolizumab in advanced, immunotherapy-naïve HNSCC.